Sai Life Sciences price hits ₹1,730.00
Key Highlights
Sai Life Sciences share price rose 8.50% to ₹1,730.00 at 09:29 IST. The company reported a net profit of ₹73 crore for the Q1 FY27 quarter.
- Sai Life Sciences rose 8.50% to ₹1,730.00 at 09:29 IST on 6 Nov 2026.
- so far was 2.37× its 20-session average.
- Q1 FY27 net profit: ₹73 crore, +21.22% on a year earlier.
- Nifty Pharma was +0.30%.
Figures as of: 09:29 IST, Friday 6 November 2026
Sai Life Sciences Ltd. (SAILIFE) share price rose 8.50% to ₹1,730.00 at 09:29 IST on Friday 6 November 2026. The trading volume reached 2.37× the 20-session average. The company filed its Q1 FY27 results on 5 November 2026, and the stock traded higher on Friday.
Sai Life Sciences share price today
| Price (09:29 IST) | ₹1,730.00 |
| Change from the previous close (₹1,594.50) | +₹135.50 (+8.50%) |
| Day’s range | ₹1,614.90 – ₹1,732.80 |
| Volume so far | 11.4 lakh shares |
| 20-session average daily volume | 4.8 lakh shares (volume so far is 2.37× that) |
| Closing prices of the previous 4 sessions | ₹1,542.30 – ₹1,594.50 |
| 52-week range (adjusted prices) | ₹783.85 – ₹1,697.00 |
| Market value at this price | ₹36,758 crore |
The share price traded between ₹1,614.90 and ₹1,732.80 during the session. Trading volume reached 11.4 lakh shares, which is 2.37× the 20-session average of 4.8 lakh shares. The current price of ₹1,730.00 is above the 52-week high of ₹1,697.00.
What has been announced
| When (IST) | Filing |
|---|---|
| Fri 6 Nov, 12:17 am | Announcement under Regulation 30 (LODR)-Investor Presentation |
| Fri 6 Nov, 12:13 am | Announcement under Regulation 30 (LODR)-Press Release / Media Release |
| Thu 5 Nov, 11:09 pm | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS |
| Thu 5 Nov, 11:05 pm | Announcement under Regulation 30 (LODR)-Change in Management |
| Thu 5 Nov, 10:54 pm | Unaudited Financial Results For The Second Quarter And Half Year Ended 30Th September 2026 |
| Thu 5 Nov, 10:48 pm | Board Meeting Outcome for Outcome Of The Board Meeting Held On 05Th November 2026. |
Q1 FY27 results at a glance
| ₹ crore | Q1 FY27 | Q1 FY26 | Change | Q4 FY26 | Change |
|---|---|---|---|---|---|
| from operations | 554 | 496 | +11.66% | 602 | −7.95% |
| 98 | 81 | +21.33% | 139 | −29.63% | |
| Net profit | 73 | 60 | +21.22% | 104 | −29.69% |
| Net profit as a share of revenue | 13.22% | 12.18% | – | 17.31% | – |
The company reported Q1 FY27 revenue from operations of ₹554 crore. Profit before tax reached ₹98 crore, which is 21.33% higher than a year earlier. Net profit for the quarter was ₹73 crore, representing a 21.22% increase compared to the same period in the previous year.
How Sai Life Sciences compares with its sector
| Change today | |
|---|---|
| Sai Life Sciences | +8.50% |
| Nifty Pharma | +0.30% |
| +0.04% | |
| Wockhardt | −2.27% |
| Abbott India | +1.01% |
| Glenmark Pharmaceuticals | −0.93% |
| Piramal Pharma | −0.85% |
The Nifty Pharma index rose 0.30% during the session. Among peers, Wockhardt was −2.27% while Abbott India gained 1.01%. Glenmark Pharmaceuticals was −0.93% and Piramal Pharma was −0.85%, while the Nifty 50 rose 0.04%.
Sai Life Sciences share price: FAQs
What is the Sai Life Sciences share price today?
₹1,730.00 at 09:29 IST on Friday 6 November 2026, up ₹135.50 or 8.50% from the previous close of ₹1,594.50.
What were Sai Life Sciences’s Q1 FY27 results?
revenue from operations of ₹554 crore (+11.66% year on year) and net profit of ₹73 crore (+21.22%), for the quarter ended 30 June 2026.
When did Sai Life Sciences announce the results?
The board meeting outcome was filed on Thu 5 Nov, 10:54 pm IST.
How is the Pharma sector doing today?
Nifty Pharma was +0.30% at 09:29 IST on Friday 6 November 2026, against +8.50% for Sai Life Sciences.
This article is for information only and is not investment advice. Prices are from the National Stock Exchange, filings from BSE announcements and results from the company’s reported figures. Calculations are by ThePip. Prices and figures move through the session; the time above says when these were read. Investments in securities are subject to market risks.